An update from Aziyo Biologics ( (ELUT) ) is now available.
On April 30, 2025, Elutia Inc. ended its distribution agreement with LeMaitre Vascular, Inc., transitioning to direct distribution of its cardiovascular products in the U.S. This strategic move is expected to enhance Elutia’s top-line growth, improve gross margins, and increase profitability. Under the leadership of Dwayne Montgomery, Elutia has established a dedicated cardiovascular sales team to ensure a smooth transition and continuity for customers. The company anticipates maintaining a premium price position and achieving approximately 80% gross margins for its cardiovascular portfolio.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
Elutia Inc. faces significant financial challenges, with declining revenue and high leverage contributing to a low financial performance score. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to negative earnings. However, the earnings call highlighted some positive developments with EluPro’s adoption and improved gross margins, slightly offsetting the negative factors. Overall, the stock’s outlook remains weak due to these substantial financial and operational challenges.
To see Spark’s full report on ELUT stock, click here.
More about Aziyo Biologics
Elutia Inc. is a company that develops and commercializes drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients. The company focuses on the cardiovascular sector with products like ProxiCor®, VasCure®, and Tyke®, which promote a healthy immune response and avoid typical foreign body reactions associated with synthetic grafts.
Average Trading Volume: 44,654
Technical Sentiment Signal: Sell
Current Market Cap: $83.37M
For detailed information about ELUT stock, go to TipRanks’ Stock Analysis page.